Status:
COMPLETED
Effect of HMG-CoA Reductase Inhibitors on the Meibomian Gland Morphology in Patients With Meibomitis
Lead Sponsor:
National Taiwan University Hospital
Conditions:
Meibomian Gland Dysfunction
Meibomitis
Eligibility:
All Genders
20-80 years
Brief Summary
This study intends to evaluate the relationship between meibomitis and statin use. Meibomitis is the predominant cause of evaporative dry eye. Higher cholesterol levels were noted in patients with mei...
Detailed Description
The purpose of our study is to assess the change of meibomian gland structure in patients during treatment with 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors using meibography....
Eligibility Criteria
Inclusion
- patients with regular HMGCR inhibitor (statin) treatment, and those with recently diagnosed dyslipidemia who were eligible to undergo 3 to 6 months of lifestyle interventions before re-evaluation for starting statin therapy
Exclusion
- patients with active eye infection, previous history of chemical or thermal injury to ocular surface, previous operation history of eyelid or conjunctiva, any known allergy or contraindications to statins, history of percutaneous coronary intervention, cerevascular accident, acute coronary syndrome, or rheumatological diseases, fish oil supplements or pregnancy were excluded
Key Trial Info
Start Date :
December 8 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 31 2020
Estimated Enrollment :
98 Patients enrolled
Trial Details
Trial ID
NCT04085016
Start Date
December 8 2016
End Date
January 31 2020
Last Update
October 14 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital
Taipei, Taiwan, 100